228 related articles for article (PubMed ID: 22264230)
1. Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment.
Happonen KE; Saxne T; Geborek P; Andersson M; Bengtsson AA; Hesselstrand R; Heinegård D; Blom AM
Arthritis Res Ther; 2012 Jan; 14(1):R15. PubMed ID: 22264230
[TBL] [Abstract][Full Text] [Related]
2. [Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis].
Marti C; Neidhart M; Gerber T; Hauser N; Michel BA; Häuselmann HJ
Z Rheumatol; 1999 Apr; 58(2):79-87. PubMed ID: 10408068
[TBL] [Abstract][Full Text] [Related]
3. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis.
Happonen KE; Saxne T; Aspberg A; Mörgelin M; Heinegård D; Blom AM
Arthritis Rheum; 2010 Dec; 62(12):3574-83. PubMed ID: 20737467
[TBL] [Abstract][Full Text] [Related]
4. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.
Ribbens C; Martin y Porras M; Franchimont N; Kaiser MJ; Jaspar JM; Damas P; Houssiau FA; Malaise MG
Ann Rheum Dis; 2002 Feb; 61(2):161-6. PubMed ID: 11796404
[TBL] [Abstract][Full Text] [Related]
5. Cartilage oligomeric matrix protein in serum in systemic lupus erythematosus and knee osteoarthritis. Preliminary communication.
Wisłowska M; Jabłońska B
Rheumatol Int; 2005 Jun; 25(5):373-8. PubMed ID: 15739097
[TBL] [Abstract][Full Text] [Related]
6. Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis.
Otteby KE; Holmquist E; Saxne T; Heinegård D; Hesselstrand R; Blom AM
Arthritis Res Ther; 2013; 15(6):R215. PubMed ID: 24330664
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment.
Skoumal M; Haberhauer G; Feyertag J; Kittl EM; Bauer K; Dunky A
Rheumatol Int; 2006 Sep; 26(11):1001-4. PubMed ID: 16485108
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis.
Skoumal M; Kolarz G; Klingler A
Scand J Rheumatol; 2003; 32(3):156-61. PubMed ID: 12892252
[TBL] [Abstract][Full Text] [Related]
9. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis.
Wisłowska M; Jabłońska B
Clin Rheumatol; 2005 Jun; 24(3):278-84. PubMed ID: 15940561
[TBL] [Abstract][Full Text] [Related]
10. COMP-C3b complexes in rheumatoid arthritis with severe extraarticular manifestations.
Happonen KE; Saxne T; Jacobsson L; Sturfelt G; Rönnelid J; Mollnes TE; Heinegård D; Turesson C; Blom AM
J Rheumatol; 2013 Dec; 40(12):2001-5. PubMed ID: 24187101
[TBL] [Abstract][Full Text] [Related]
11. Enhanced COMP catabolism detected in serum of patients with arthritis and animal disease models through a novel capture ELISA.
Lai Y; Yu XP; Zhang Y; Tian Q; Song H; Mucignat MT; Perris R; Samuels J; Krasnokutsky S; Attur M; Greenberg JD; Abramson SB; Di Cesare PE; Liu CJ
Osteoarthritis Cartilage; 2012 Aug; 20(8):854-62. PubMed ID: 22595227
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of cartilage oligomeric matrix protein are elevated in rheumatoid arthritis, but not in inflammatory rheumatic diseases such as psoriatic arthritis, reactive arthritis, Raynaud's syndrome, scleroderma, systemic lupus erythematosus, vasculitis and Sjögren's syndrome.
Skoumal M; Haberhauer G; Feyertag J; Kittl EM; Bauer K; Dunky A
Arthritis Res Ther; 2004; 6(2):73-4. PubMed ID: 15059267
[No Abstract] [Full Text] [Related]
13. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
15. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation.
Neidhart M; Hauser N; Paulsson M; DiCesare PE; Michel BA; Häuselmann HJ
Br J Rheumatol; 1997 Nov; 36(11):1151-60. PubMed ID: 9402858
[TBL] [Abstract][Full Text] [Related]
16. Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments.
Morozzi G; Fabbroni M; Bellisai F; Pucci G; Galeazzi M
Ann N Y Acad Sci; 2007 Jun; 1108():398-407. PubMed ID: 17894003
[TBL] [Abstract][Full Text] [Related]
17. Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners.
Neidhart M; Müller-Ladner U; Frey W; Bosserhoff AK; Colombani PC; Frey-Rindova P; Hummel KM; Gay RE; Häuselmann H; Gay S
Osteoarthritis Cartilage; 2000 May; 8(3):222-9. PubMed ID: 10806050
[TBL] [Abstract][Full Text] [Related]
18. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study.
Roux-Lombard P; Eberhardt K; Saxne T; Dayer JM; Wollheim FA
Rheumatology (Oxford); 2001 May; 40(5):544-51. PubMed ID: 11371663
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy.
Niki Y; Takeuchi T; Nakayama M; Nagasawa H; Kurasawa T; Yamada H; Toyama Y; Miyamoto T
PLoS One; 2012; 7(5):e37447. PubMed ID: 22629396
[TBL] [Abstract][Full Text] [Related]
20. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
Kawashiri SY; Kawakami A; Ueki Y; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Origuchi T; Ida H; Eguchi K
Joint Bone Spine; 2010 Oct; 77(5):418-20. PubMed ID: 20864374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
